Contact Number:
Email:
Peter has a BSc honours degree in Biochemistry from Imperial College London and an MSc in Management of Intellectual Property from Queen Mary, University of London.
Peter entered the profession in 2009 as a trainee patent attorney working in-house, joined Sagittarius IP in 2011, based in the Marlow office and became a partner in 2019. He is a UK Chartered Patent Attorney and European Patent Attorney. He completed CIPA’s Litigation Skills Course in 2015, and holds the Intellectual Property Litigation Certificate.
Peter’s practice includes the preparation, filing and prosecution of UK, European and PCT (international) patent applications, freedom to operate analysis and IP due diligence. His cases relate to subject matter spanning many different areas of pharmaceuticals and biotechnology, with a particular focus on monoclonal antibodies, domain antibodies, bispecific antibodies and antibody-drug-conjugates as well as vaccines, antibody technology and medical devices. He has experience of working with clients ranging from small biotechnology firms to large pharmaceutical companies.
Contact Number:
Email:
Peter has a BSc honours degree in Biochemistry from Imperial College London and an MSc in Management of Intellectual Property from Queen Mary, University of London.
Peter entered the profession in 2009 as a trainee patent attorney working in-house, joined Sagittarius IP in 2011, based in the Marlow office and became a partner in 2019. He is a UK Chartered Patent Attorney and European Patent Attorney. He completed CIPA’s Litigation Skills Course in 2015, and holds the Intellectual Property Litigation Certificate.
Peter’s practice includes the preparation, filing and prosecution of UK, European and PCT (international) patent applications, freedom to operate analysis and IP due diligence. His cases relate to subject matter spanning many different areas of pharmaceuticals and biotechnology, with a particular focus on monoclonal antibodies, domain antibodies, bispecific antibodies and antibody-drug-conjugates as well as vaccines, antibody technology and medical devices. He has experience of working with clients ranging from small biotechnology firms to large pharmaceutical companies.
Peter has a BSc honours degree in Biochemistry from Imperial College London and an MSc in Management of Intellectual Property from Queen Mary, University of London.
Peter entered the profession in 2009 as a trainee patent attorney working in-house, joined Sagittarius IP in 2011, based in the Marlow office and became a partner in 2019. He is a UK Chartered Patent Attorney and European Patent Attorney. He completed CIPA’s Litigation Skills Course in 2015, and holds the Intellectual Property Litigation Certificate.
Peter’s practice includes the preparation, filing and prosecution of UK, European and PCT (international) patent applications, freedom to operate analysis and IP due diligence. His cases relate to subject matter spanning many different areas of pharmaceuticals and biotechnology, with a particular focus on monoclonal antibodies, domain antibodies, bispecific antibodies and antibody-drug-conjugates as well as vaccines, antibody technology and medical devices. He has experience of working with clients ranging from small biotechnology firms to large pharmaceutical companies.
Peter has a BSc honours degree in Biochemistry from Imperial College London and an MSc in Management of Intellectual Property from Queen Mary, University of London.
Peter entered the profession in 2009 as a trainee patent attorney working in-house, joined Sagittarius IP in 2011, based in the Marlow office and became a partner in 2019. He is a UK Chartered Patent Attorney and European Patent Attorney. He completed CIPA’s Litigation Skills Course in 2015, and holds the Intellectual Property Litigation Certificate.
Peter’s practice includes the preparation, filing and prosecution of UK, European and PCT (international) patent applications, freedom to operate analysis and IP due diligence. His cases relate to subject matter spanning many different areas of pharmaceuticals and biotechnology, with a particular focus on monoclonal antibodies, domain antibodies, bispecific antibodies and antibody-drug-conjugates as well as vaccines, antibody technology and medical devices. He has experience of working with clients ranging from small biotechnology firms to large pharmaceutical companies.
